<DOC>
	<DOCNO>NCT02375724</DOCNO>
	<brief_summary>The aim present study evaluate effect aclidinium bromide 400 μg BID compare placebo COPD symptom symptomatic patient population moderate COPD chronic bronchitis , particularly assess effect cough use specific tool assess occurrence impact relevant COPD symptom .</brief_summary>
	<brief_title>BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . Adult male nonpregnant , nonlactating female age ≥40 . Women childbearing potential follow specific study requirement . 2 . Current excigarette smoker , smoke history least 10 packyears 3 . Patients clinical diagnosis moderate COPD , post bronchodilator test available within 6 month prior Visit 1 ( Screening ) , FEV1 ≥50 % &lt; 80 % FEV1/FVC &lt; 70 % . 4 . Symptomatic patient CAT≥10 Screening Randomisation Visit ( Visit 1 2 ) 5 . Clinical Diagnosis Chronic Bronchitis ( define `` presence cough sputum production least 3 month 2 consecutive year '' ) 6 . Patient eligible able participate trial consent write purpose nature investigation explain 1 . History current diagnosis asthma . 2 . Patients suffer moderate severe COPD exacerbation last year prior Visit 1 ( Screening ) runin period . 3 . Patients develop respiratory tract infection within 6 week Visit 1 ( Screening ) runin period . 4 . Clinically significant respiratory cardiovascular condition think contribute cough likely interfere conduct study . 5 . Patient investigator 's opinion may need start pulmonay rehabilitation program study and/or patient started/finished within 3 month prior Screening Visit . 6 . Use longterm oxygen therapy . 7 . Patients nonstable treatment angiotensinconverting enzyme inhibitor opiates . 8 . Patients treatment mucolytics , antihistamine , expectorant antitussive drug include overthecounter medication . 9 . Patient maintain regular day/night , waking/sleeping cycle include night shift worker . 10 . Patient clinically relevant abnormality result physical examination Visit 1 ( Screening ) 11 . Patient history hypersensitivity reaction inhale anticholinergic , sympathomimetic amine , inhaled medication component thereof ( include report paradoxical bronchospasm ) . 12 . Patient know narrowangle glaucoma , symptomatic bladder neck obstruction , acute urinary retention , patient symptomatic nonstable prostatic hypertrophy . 13 . Patient know noncontrolled history infection human immunodeficiency virus ( HIV ) and/or active hepatitis 14 . Current diagnosis cancer basal squamous cell skin cancer 15 . Patient serious uncontrolled physical mental dysfunction 16 . Patient history ( within 2 year prior Screening Visit ) drug and/or alcohol abuse may prevent study compliance base investigator judgment . 17 . Patient unlikely cooperative comply study procedures 18 . Patient treat investigational drug within 30 day ( 6 halflives , whichever long ) prior Visit 1 ( Screening ) . 19 . Patient intend use concomitant medication permit protocol undergone require stabilization period prohibit medication . 20 . Any condition , investigator 's opinion , might indicate patient unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>110 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>COPD</keyword>
</DOC>